[Serum lipid-bound sialic acid as a marker in lung cancer patients].
[Serum lipid-bound sialic acid as a marker in lung cancer patients].
复制标题
[血清脂质结合唾液酸作为肺癌患者的标志物]。
DOI：
10.11389/jjrs1963.28.1599
复制
发表时间：
1990
期刊：
影响因子：
--
通讯作者：
N. Iwahashi
中科院分区：
文献类型：
--
作者：
N. Iwahashi
为探讨血清脂质结合唾液酸（LSA）作为肺癌患者肿瘤标志物的价值，采用Katopodis和Stock建立的方法，对85例原发性肺癌患者、42例肺良性疾病患者和22例健康对照者血清LSA水平进行了测定。原发性肺癌患者的平均血清LSA浓度[32.4 ± 16.4（SD）mg/dl]显著高于良性肺病患者（22.4 ± 12.4 mg/dl）或健康对照组（17.2 ± 4.5 mg/dl）。60%的原发性肺癌患者血清LSA水平高于健康对照组的平均值加2SD（26.0mg/dl），其中I、II期9例中1例（11.1%），III、IV期76例中50例（65.8%），良性肺部疾病35.4%。血清LSA浓度在各细胞类型间无显著性差异。39.8%的肺癌患者血清癌胚抗原（CEA）升高（> 5.0ng/ml）。由于血清LSA和CEA水平之间的相关性较差，当这两种标志物联合使用时，本研究中71.1%的肺癌病例显示血清LSA或CEA水平升高，或两者均升高。此外，在强化化疗期间随访的小细胞肺癌患者中，血清LSA水平几乎与临床病程平行变化。提示血清LSA可作为肺癌患者的一个有用的生化指标。
To evaluate the usefulness of serum lipid-bound sialic acid (LSA) as a tumor marker in patients with lung cancer, its serum levels were determined in 85 patients with primary lung cancer, 42 patients with benign pulmonary diseases and 22 healthy controls by the method developed by Katopodis and Stock. The mean serum LSA concentration was significantly higher in the patients with primary lung cancer [32.4 +/- 16.4 (SD) mg/dl] than that in the patients with benign pulmonary diseases (22.4 +/- 12.4 mg/dl) or in healthy controls (17.2 +/- 4.5 mg/dl). The serum LSA level was elevated above the mean value plus 2 SD for the healthy controls (26.0 mg/dl) in 60% of all cases with primary lung cancer including 1 of 9 (11.1%) in stages I and II and 50 of 76 (65.8%) in stages III and IV and 35.4% of the patients with benign pulmonary diseases. No significant difference was observed in serum LSA concentration among each cell type of lung cancer. Serum carcinoembryonic antigen (CEA) was elevated (greater than 5.0 ng/ml) in 39.8% of the patients with lung cancer. As there was poor correlation between serum LSA and CEA levels, when these two markers were used in combination, 71.1% of the cases with lung cancer in this study showed elevated levels of either serum LSA or CEA, or both. Moreover, in the patients with small cell lung cancer followed up during intensive chemotherapy, serum LSA levels changed almost parallel with the clinical course. These results indicate that serum LSA may be a useful biochemical marker in lung cancer patients.
Kannagi, R.、Fukushi, Y.、Tachikawa, T.、Noda, A.、Shin, S.、Shigeta, K. 等人：“表达岩藻糖基或唾液酸基的癌症相关血清糖蛋白抗原的定量和定性表征
DOI：
--
发表时间：
--
期刊：
影响因子：
--
作者：
通讯作者：
--